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Abstract
Background: Capilia TB is a simple immunochromatographic assay based on the detection of MPB64 antigen
specifically secreted by the Mycobacterium tuberculosis complex (MTC). Capilia TB was evaluated for rapid identification
of MTC from BACTEC MGIT 960 and BACTEC 9120 systems in Kampala, Uganda. Since most studies have mainly dealt
with respiratory samples, the performance of Capilia TB on blood culture samples was also evaluated.
Methods: One thousand samples from pulmonary and disseminated tuberculosis (TB) suspects admitted to the JCRC
clinic and the TB wards at Old Mulago hospital in Kampala, Uganda, were cultured in automated BACTEC MGIT 960 and
BACTEC 9120 blood culture systems. BACTEC-positive samples were screened for purity by sub-culturing on blood agar
plates. Two hundred and fifty three (253) samples with Acid fast bacilli (AFB, 174 BACTEC MGIT 960 and 79 BACTEC
9120 blood cultures) were analyzed for presence of MTC using Capilia TB and in-house PCR assays.
Results: The overall Sensitivity, Specificity, Positive and Negative Predictive values, and Kappa statistic for Capilia TB
assay for identification of MTC were 98.4%, 97.6%, 97.7%, 98.4% and 0.96, respectively. Initially, the performance of
in-house PCR on BACTEC 9120 blood cultures was poor (Sensitivity, Specificity, PPV, NPV and Kappa statistic of
100%, 29.3%,7%, 100% and 0.04, respectively) but improved upon sub-culturing on solid medium (Middlebrook
7H10) to 100%, 95.6%, 98.2%, 100% and 0.98, respectively. In contrast, the Sensitivity and Specificity of Capilia TB
assay was 98.4% and 97.9%, respectively, both with BACTEC blood cultures and Middlebrook 7H10 cultured
samples, revealing that Capilia was better than in-house PCR for identification of MTC in blood cultures.
Additionally, Capilia TB was cheaper than in-house PCR for individual samples ($2.03 vs. $12.59, respectively), and
was easier to perform with a shorter turnaround time (20 min vs. 480 min, respectively).
Conclusion: Capilia TB assay is faster and cheaper than in-house PCR for rapid identification of MTC from BACTEC
MGIT 960 and BACTEC 9120 culture systems in real-time testing of AFB positive cultures.
Background
Genetically related species of the Mycobacterium tuber-
culosis complex (MTC; M .t u b e r c u l o s i s ,M .b o v i s ,M .
bovis BCG, M. africanum, M. caprae and M. cannetti)
cause tuberculosis (TB) [1], a global disease that affects
one third of the human population [2,3]. Tuberculosis
and HIV form a deadly synergy [4] with approx. 75% of
people with HIV/TB co-infection living in sub-Saharan
Africa [2,5]. Of the 22 high TB burdened countries,
Uganda now ranks 16 with an estimated incidence of
452 cases per 100,000 individuals [3]. Kampala, the capi-
tal of Uganda with approx. 2 million people, accounts
for ~30% of the nation’s TB burden [6].
Accurate diagnosis of TB is crucial for efficient patient
management; however, conventional approaches to TB
diagnosis still rely on tests with major limitations [7-10].
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has low sensitivity (30% to 60%) especially in patients co-
infected with HIV. The chest X-ray, often used as a supple-
mentary test in smear-negative pulmonary TB also has low
specificity. Solid culture as a confirmatory test is expensive,
lengthy (up to 8 weeks) and is not widely available in
resource limited settings [11]. The World Health Organi-
zation (WHO) recommends use of liquid cultures in high
TB burdened countries due to advantages of rapid detec-
tion and incremental yield in comparison with the solid
media [12]. However, liquid culture methods are prone to
contamination and usually support growth of nontubercu-
lous mycobacteria (NTM), which may as well inhabit the
upper respiratory tract and cause disease in immunocom-
promised patients [13]. This may lead to reporting false
results especially during drug sensitivity testing in that
NTM are inherently resistant to common anti-TB drugs
[14,15]. Further, MTC and NTM cause clinically different
clinical symptoms hence prompt identification is crucial
for appropriate patient management [16-18].
Recently, nucleic acid amplification tests (NAAT) have
been introduced for rapid identification of mycobacteria
directly in sample or culture. As such, an in-house PCR
assay for identification of MTC was introduced at the
Joint Clinical Research Centre (JCRC) in Kampala,
Uganda. However, there have been some shortcomings
with this method: turnaround time is long (~8 hours)
leading to delays in reporting results. Further, we have
encountered high rates of false negatives with blood cul-
tures (i.e., templates prepared from BACTEC 9120 sys-
tem, unpublished observations). Conventional molecular
methods are still technologically expensive: reagents
require cold storage and shipping; methods are labor-
intensive and require separate rooms for DNA extrac-
tion, amplification and detection. Batching of samples is
usually required for cost effectiveness.
Capilia TB assay is an immunochromatographic
method that detects MPB64 protein secreted from MTC
bacilli into the culture medium [12]. Originally found in
M. bovis, similar proteins (i.e. orthologous to MPB64)
have been detected in all MTC species and are report-
edly rare in NTM. Capilia TB assay is rapid, simple and
does not require special equipment [19,20]; it has been
found efficient for identification of MTC in South
Africa, Thailand and Zambia [20,21]. In this study, the
performance of Capilia TB assay was evaluated for rapid
detection of MTC from BACTEC MGIT 960 and BAC-
TEC 9120 systems in Kampala, Uganda. Additionally,
the performance of Capilia TB on blood cultures was
evaluated since previous studies mainly dealt with
respiratory samples. The overall Sensitivity, Specificity,
PPV and NPV of Capilia TB assay were high and in
agreement with values obtained elsewhere.
Methods
Study setting and design
Samples for this cross sectional study were obtained
from pulmonary and disseminated TB suspects (at base-
line, follow up and retreatment cases) admitted to the
JCRC clinic and the TB wards at Old Mulago hospital
in Kampala, Uganda, from April 2008 to May 2009.
Sputum and gastric samples in sterile 50 ml Falcon
tubes were obtained directly from TB suspects and
injected into sterile 50 ml Falcon tubes while blood
samples were drawn intravenously by a study nurse and
inoculated into BACTEC 9120 blood culture bottles.
Samples were cultured in automated BACTEC MGIT
960 and BACTEC 9120 systems (samples from Old
Mulago hospital were transported daily by courier to the
JCRC for culture). A convenient sample size (i.e. which
did not affect patient management) of 253 AFB-positive
blinded samples was considered; these were selected in
batches of 30 upon detection of AFB (within 42 days;
AFB-negative samples in the same period were
excluded). In-house PCRs were performed at the Mole-
cular Biology Laboratory, Makerere University College
of Health Sciences (MakCHS) while Capilia TB assays
were performed at the JCRC.
Sample processing and culture
Sputum and gastric samples were processed in Biosafety
cabinet class II following the standard N-Acetyl L-
cysteine (NALC)/NaOH method [22]. Briefly, an equal
volume of decontamination/digestion buffer (6% NaOH,
2.9% Na-citrate and NALC) was added to each sample,
vortexed for 5 min and incubated at room temperature
for 15 min. The digested samples were neutralized with
phosphate buffer (pH 6.8) and mixed thoroughly by
inversion. The samples were centrifuged at 3000 g for
15 minutes, and the sediment suspended in 2.5 ml phos-
phate buffer (pH 6.8). Then, 0.8 ml of the growth sup-
plement, Polymxin B, Amphoterin B, Nalidixic acid,
Trimetroprim and Azlocillin (PANTA) was added to the
Mycobacterium Growth Indicator Tubes (MGIT), to
which 0.5 ml of the digested sample was added and
incubated in BACTEC MGIT 960 system for 6 weeks.
For blood cultures, the barcodes were scanned prior to
incubating directly for 6 weeks in the BACTEC 9120
system. Ziehl Neelsen (ZN) smears were performed on
BACTEC MGIT 960 and BACTEC 9120 samples with
microbial growth to determine the presence of AFB.
Purity checks were performed by sub-culturing on blood
agar plates.
Capilia TB assays
C a p i l i aT Ba s s a y( T A U N ,N u m a z u ,J a p a n )w a sp e r -
formed on AFB-positive BACTEC samples following the
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grew on solid media (Middlebrook 7H10), a suspension
was made by mixing a single colony with 0.2 ml extrac-
tion buffer and vortexed; the resultant suspension was
then applied onto the Capilia TB strip (following the
manufacture’s guidelines).
In-house PCR
The performance of Capilia TB assay was compared
with that of in-house PCR, which we used as a baseline
identification test for MTC. The in-house PCR protocol
was based on the detection of IS6110, which is unique
to members of the MTC [22]. Templates were prepared
from BACTEC cultures and used in a PCR-amplification
procedure previously described [22]. Furthermore, MTC
were identified to species level using the regions of dif-
ference (RD) genotyping method as previously described
by Asiimwe et al, 2008 [23]. All the strains belonged to
M. tuberculosis sensu strict [23].
Quality control
To avoid cross contamination, separate rooms and
equipment were used for sample preparation, DNA
extraction and preparation of amplification reactions. In
addition, positive and negative controls were always
included in the PCRs. Amplification reactions and PCR
products were opened in separate UV hoods each
located in separate rooms. For cultures, aerosol resistant
tips 160 were used and changed for each sample as pre-
viously described [22]. Samples with discrepant 161
results were analyzed with the Hains MTB identification
kit (Hains life sciences, Nehren, 162 Germany). Blood
samples in which AFB grew were further sub-cultured
on Middlebrook 7H10 163 agar and analyzed again with
both in-house PCR and Capilia TB assay.
Ethical consideration
Ethical approval was obtained from the institutional
r e v i e wb o a r do ft h eJ C R Ca n dt h eU g a n d aN a t i o n a l
Council for Science and Technology. Written informed
consent was obtained from all the study participants.
Results and discussion
Performance of capilia TB for identification of MTC in
BACTEC cultures
In this study, the overall Sensitivity, Specificity, PPV and
NPV of Capilia TB assay were high and in agreement
with values obtained in other studies [17,20,21,24]. Of
the 253 AFB positive samples, 79 (31%, 79/253) were
BACTEC 9120 blood cultures while 174 (69%, 174/253)
were BACTEC MGIT 960 cultures. M. tuberculosis
complex bacilli were identified in 129 samples (51%,
129/253) by Capilia TB and in 130 (51%, 130/253) by
in-house PCR. Capilia identified 124 (49%, 124/253)
NTM while 130 (51%, 130/253) were identified by in-
house PCR. The overall sensitivity, specificity, PPV and
NPV of Capilia TB assay were 98.4%, 97.6%, 97.7%, and
180 98.4%, respectively (Table 1). The Kappa statistic
was 0.96 indicating almost perfect agreement between
the tests.
Performance of capilia TB assay for identification of MTC
in pure vs. Contaminated cultures
Of the 253 BACTEC AFB-positive cultures, 139 (55%,
139/253) were contaminated while 114 (45%, 114/253)
were pure. Screening contaminated cultures (see Table
2) with Capilia TB assay for MTC revealed Sensitivity,
Specificity, PPV and NPV of 95.1%, 99%, 97.5% and 98%
respectively, which values were in a similar range with
those for pure cultures (i.e., 98.9%, 96.3%, 98.9% and
96.3% respectively). The Kappa statistics for both tests
in contaminated and pure samples were 0.98 and 0.95
(almost perfect agreement), respectively.
Performance of capilia TB in identification of MTC from
BACTEC blood cultures and sub-cultures on solid media
Prior to sub-culture on Middle brook 7H10 plates, 57
(72%, 57/79) of the 79 AFB-positive BACTEC 9120
blood cultures were identified as MTC by Capilia TB
assay while only four (5%, 4/79) were identified by in-
house PCR. Additionally, Capilia TB identified 22 (28%,
2 2 / 7 9 )b l o o dc u l t u r e sa sN T Mw h i l ei n - h o u s eP C R
identified 75 (95%, 75/79). The Sensitivity, Specificity,
PPV and NPV of Capilia TB assay on direct blood cul-
tures were 100%, 29.3%, 7% and 100% respectively
(Table 3). The Kappa statistic was 0.04, indicating slight
agreement between capilia and in-house PCR when used
on direct blood culture. Following sub-culturing on
Middlebrook 7H10 plates, Capilia TB identified the
same number of samples as MTC (i.e. 57/79, 72%) while
in-house PCR identified 56 (i.e. 52 more, 71%). When
the initial in-house PCR negative blood cultures were
tested by the Hains MTB test, 57 (72%, 57/79) samples
were confirmed as MTC, which was 100% in agreement
with the Capilia TB assay. For in-house PCR, the specifi-
city (29.3% vs. 95.6%) and PPV (7% vs. 98.2%) improved
Table 1 Sensitivity and Specificity of Capilia TB in
comparison with in-house PCR
PCR
Capilia Positive Negative Total
Positive 127 2 129
Negative 3 121 124
Total 130 123 253
Sensitivity (Se) = 98.4%; Specificity (Sp) = 97.58%; Positive predictive value
(PPV) = 97.7%; Negative predictive value (NPV) = 98.4% and Kappa statistic (#)
= 0.96 (almost perfect)
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whereas values for Capilia TB remained unchanged
(Table 3). This confirmed presence of MTC in the 57
blood culture samples as initially identified by Capilia
TB assay. The agreement between the two tests was
almost perfect (kappa statistic = 0.98). Thus, Capilia TB
assay was more efficient than in-house PCR at identify-
ing MTC in BACTEC blood cultures. This demon-
strated the superiority of Capilia TB assay to in-house
PCR for identification of MTC in various samples. For
in-house PCR, the initial high number of false negatives
was probably due to PCR inhibitors in blood (such as
haeme and/or porphyrins from lysed erythrocytes
believed to inhibit Taq polymerase [25]), since PCRs on
7H10 samples turned positive. In terms of materials and
labor, the overall cost per sample for identification of
MTC with Capilia TB was cheaper than that for in-
house PCR (Table 4). Moreover, the cost estimations
are more expensive even after excluding equipment
(such as thermocyclers).
Limitations
Due to limited resources, we could not sequence-con-
firm MTC species nor perform biochemical assays,
which are regarded as gold standards for MTC identifi-
cation. Furthermore, AFB were detected with ZN stain-
ing which is not very sensitive, implying that MTC in
ZN negative samples were probably missed. Further,
Table 2 Performance of Capilia TB for identification of MTC on contaminated and pure BACTEC cultures
PCR
aCapilia Positive Negative Total
Positive 39 1 40
Negative 29 7 9 9
Total 41 98 139
bCapilia Positive 86 1 87
Negative 12 6 2 7
Total 87 27 114
aPerformance (%) of Capilia TB on contaminated BACTEC cultures. The Se, Sp, PPV and NPV were 95.1, 99, 97.5 and 98, respectively.
bPerformance (%) of Capilia
TB in pure BACTEC cultures. The Se, Sp, PPV, NPV & (#) were 98.9, 96.3, 98.9, 96.3, and (0.98 & 0.95), repectively, (almost perfect agreement)
Table 3 Performance of Capilia TB for identification of MTC in direct blood cultures and on solid media (7H10 sub-
cultures)
PCR
Capilia Blood culture
a 7H10
b
Positive Negative Total Positive Negative Total
Positive 45 3 5 7 5 6 15 7
Negative 0 22 22 0 22 22
Total 4 7 57 9 5 62 37 9
aThe performance (%) of Capilia TB on templates picked directly from blood cultures. The Se, Sp, PPV and NPV were, 100, 29, 7 and 100, respectively.
bPerformance (%) on Capilia TB assay on Middlebrook 7H10 media. The Se, Sp, PPV, NPV & (#) were 100, 95.6, 98.2, 100 and (0.98), respectively (almost perfect
agreement)
Table 4 Cost per test for performing Capilia TB in comparison with in-house PCR
Materials per test PCR Capilia
Quantity Cost
a Quantity Cost
a
Cryovial 1 0.34 -
Pasteur pipettes 1 0.19 1 0.19
Capilia test cassette - - 1 1.84
PCR reagents 1 10.00 -
Quality control PCR 1 0.53 -
Pipette tips 8 0.40 -
PCR tubes 1 0.05 -
Total cost
a 12.59 2.03
-Not applicable;
aUS dollars
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Page 4 of 6mutations in the mpb64 gene usually lead to detection
of false negatives [12,24] while NTM testing positive
with Capilia TB tests have been recently reported
[12,24]; these, coupled with the failure to distinguish
members of the MTC and failure to work on clinical
specimens somehow negate the efficiency of Capilia TB
assays. These shortcomings are also re-iterated in the
manufacturer’s kit inserts implying that the kit should
be cautiously used.
Conclusion
Capilia TB assay performed better and was cheaper than
IS6110 in-house PCR for rapid identification of MTC
from BACTEC MGIT 960 and BACTEC 9120 systems.
The optimal performance of in-house PCR on blood
cultures requires an additional isolation step on solid
media for optimum performance.
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